Progress of targeted therapy of intrahepatic cholangiocarcinoma
10.3760/cma.j.issn.1007-8118.2019.12.019
- VernacularTitle: 肝内胆管癌的靶向治疗研究进展
- Author:
Yeming ZHOU
1
;
Wei JIANG
2
;
Jing HUANG
2
;
Yongfei HUA
2
;
Caide LU
2
Author Information
1. Medical School of Ningbo University, Ningbo 315211, China
2. Department of Hepatobiliary and Pancreatic Surgery, Eastern Branch, Ningbo Medical Center Li Huili Hospital, Ningbo 315040, China
- Publication Type:Review
- Keywords:
Bile duct neoplasm;
Cholangiocarcinoma;
Intrahepatic cholangiocarcinoma;
Molecular targeted therapy;
Progress
- From:
Chinese Journal of Hepatobiliary Surgery
2019;25(12):956-960
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing year by year. For most patients, surgical resection is not suitable when they are diagnosed as ICC. Conventional chemotherapy and radiotherapy are not effective for the long-term survival rate of ICC patients and lead to the poor overall prognosis. In recent years, with the deepening understanding about the molecular mechanism of biliary malignant tumors, some key genes and signaling pathways related to the pathogenesis of ICC have been identified, providing new ideas for the targeted therapy. In this paper, major molecular mechanisms and targeted therapies of ICC are reviewed.
